Vendor Intelligence Report: Orbitrex Peptides
Published 12 Nov 2026. 31-page investigative report on who is behind Orbitrex Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Orbitrex is a per-product decision, not a blanket green light. Across 51 Finnrick lab tests, Orbitrex posts 40 pass / 8 fail — an overall pass rate of 78%. Retatrutide is the strongest reason to consider the vendor, with GHK-Cu also favorable; TB-500 is the clearest avoid signal, while BPC-157 and tirzepatide need cautious comparison against stronger product-specific vendors. Stricter purity/fill grading narrows the picture further.
Identity is stronger than many gray-market peers: USPTO, Texas Comptroller, OpenCorporates and .is WHOIS records connect the brand to Calvin Newton and Fast Fission Street Holding LLC. The tradeoff is operational opacity: the storefront omits the legal entity, uses a UPS Store mailbox, names no manufacturer or batch-release officer, and its own RUO disclaimer says Orbitrex is not the manufacturer and does not inspect sealed containers.
The highest-severity buyer hazard is brand confusion. The investigation documents live .co and hyphenated clones copying the Orbitrex catalog, BBB complaints tied to imposter domains taking irreversible payments, and a Titan Biomethods social channel that names the official site while its Facebook page points to a suspended lookalike. The official store’s direct card acceptance is a relative positive, but IDEM Pay/token flows and clone checkout labels make domain verification critical.
Reputation signals are mixed rather than empty. Orbitrex publishes a deep COA archive and receives positive third-party documentation scores, but Trustpilot removed the profile, affiliate-code promotion is widespread and unevenly disclosed, and a detailed tirzepatide lot complaint remains unresolved. FDA warning-letter and Lilly retatrutide-suit checks did not name Orbitrex in the materials reviewed; that is a point-in-time negative finding, not a clearance.
Inside the full report:
- Appendix A per-product pass/fail rates and methodology-divergence charts for all 6 tested products
- Texas Comptroller, USPTO, OpenCorporates and ISNIC ownership records
- Clone-domain checkout captures, BBB complaint exhibits and Titan Biomethods channel analysis
- COA archive review covering 186 certificates, lab mix and shared-lot caveats
- Payment-stack and affiliate-disclosure mapping, including IDEM Pay and referral-code evidence
Risk assessment
- Copycat / brand-confusion risk — high: Live .co clones copy the catalog and checkout, imposter complaints document losses, Titan Biomethods bridged to a suspended lookalike, and Orbitrex lacks a prominent official-domains verification page.
- TB-500 quality risk — high: TB-500 is the clearest avoid signal: 2 tests, 0 pass / 2 fail, Finnrick rating 34.12%.
- BPC-157 and Tirzepatide quality risk — medium: BPC-157 is weak at 6 tests, 4 pass / 2 fail, 55.57%; Tirzepatide is cautious at 7 tests, 5 pass / 2 fail, 75.96%.
- Batch-release / manufacturer transparency risk — medium: The site names no QA or release officer, no manufacturer, and its RUO disclaimer says Orbitrex is not the manufacturer and does not open sealed containers.
- Affiliate-promotion disclosure risk — medium: Multiple captured promoters used Orbitrex codes or referral links with no or unclear disclosure, making review and social-proof signals commercially contaminated.